Blinatumomab Approval Expanded Based on MRD [News in Brief]

The decision marks the first time the agency has approved an ALL drug using minimal residual disease as an endpoint.

from Cancer via ola Kala on Inoreader https://ift.tt/2HwiJlj
via IFTTT